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SUMMARY
Purpose The aim of this study is to analyze the consumption patterns of medicaments among motor vehicle drivers who
attend ‘Medical Driving Test Centres’ and the relation between habitual consumption of medicaments and fitness to drive.
Methods The study was carried out on 8043 drivers who attended 25 Medical Driving Test Centres.
Results 24.7% of drivers chronically consume medicaments while 6.8% consume medicaments along with alcohol every
day. Of those who chronically consume medicaments with a warning about the medications on driving, 65.8% were con-
sidered ‘fit’ to drive, 27.3% ‘fit with restrictions’, 5.1% ‘suspended’ and 0.4% ‘unfit’.
Conclusions The results show how frequent the consumption of medicaments along with alcohol is and that the great
majority of drivers who take medicaments are considered fit to drive. Copyright# 2003 John Wiley & Sons, Ltd.
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INTRODUCTION
Road accidents represent a major health problem
worldwide and their prevention is on a high priority.
A factor that may influence their occurrence is driving
under the effects of psychotropic substances.
Although alcohol is the main substance involved in
these accidents, the consumption of medicaments is
also increasing, resulting in growing interest in this
subject. Estimates indicate that at least 10% of the
persons killed or injured in traffic accidents had con-
sumed psychotropic medication and that could have
been a contributory factor.1
Within the EU, the drug–driving (either illegal and/
or medicinal drugs) relation can be seen from a dual
perspective: First, European countries have different
regulations concerning illegal and medicinal drug–
driving, sanctioning those under the influence of sub-
stances (both illegal and medicinal drugs) who show
impaired driving ability. Obviously, this situation
applies to both those who take illegal and/or medicinal
drugs occasionally, and to those who take these habi-
tually. Unlike with alcohol, establishing a dose con-
centration–effect relationship is much more
complex.2 Thus, concentration levels above which
driving should be prohibited is still difficult to estab-
lish,2 although recently a benzodiazepine drug–
concentration relationship with impairment has been
reported which opens the possibility to establish con-
centration limits.3 At present, legislators have two
options4,5: (i) ‘zero tolerance’ or (ii) to evaluate
impairment by specifically trained police officers on
the roadside. These approaches are not mutually
exclusive. Zero-tolerance, that is, ‘per se’ laws in
which analytical cut-off levels for illicit drugs are
established, exists in some countries (e.g. Belgium,
Germany, Sweden and Portugal). However in Sweden,
medicinal drugs—i.e. benzodiazepines—are included
if they are not on prescription or at high levels). More-
over, research to develop practical and reliable detec-
tion equipment for roadside checking for drugs and
medicines should continue.4,5
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Second, current European legislation does not
permit the issuing or renewal of licences for those
without adequate driving ability. The different EU
member countries possess national regulations on
driving licences (Royal Decree 772/1997 for Spain)
in accordance with Council Directive 91/439/EEC
(29 July 1991 on driving licences).5,6 This indicates
that ‘driving licences shall not be issued to or renewed
for applicants or drivers who regularly use psychotro-
pic substances, which can hamper the ability to drive
safely where the quantities absorbed are such as to
have an adverse effect on driving. This shall apply
to all other medicinal products or combinations of
medicinal products which affect the ability to drive’.
Member states implement this regulation differently.
For example, legislation in Spain establishes that to
obtain a driving licence, or to renew it, a medical-
psychological examination, carried out in specific
‘Medical Driving Test Centres’, is obligatory.5
The relation between medicaments and fitness to
drive is complex as the medicaments used to treat ill-
ness may, by their very nature, impair a person’s fit-
ness to drive.6 However, the joint consumption of
alcohol and medicaments, which is frequent,7 may
cause even greater impairment.
Furthermore, one problem is that from the point of
view of traffic authorities, they usually consider illegal
and medicinal drugs together regarding either driving
under the influence or fitness to drive, as they share
some similarities when compared with alcohol. Both
should be treated as two separate issues where driving
is concerned.6 The present study focuses on medicinal
drugs and fitness to drive.
The aim of this study is to: (i) analyze medicament
consumption patterns among drivers attending ‘Medi-
cal Driving Test Centres’ including their alcohol con-
sumption and (ii) analyze the relation between habitual
consumption of medicaments and fitness to drive.
METHODS
The study was planned as a multi-centre based study
on a national scale. A full description of methods is
reported elsewhere.5,8 A sample of 8043 drivers
(5435 (67.6%) male, 2608 (33.4%) female) attending
25 Medical Driving Test Centres to obtain or renew
driving licences were approached, informed about
the study, stressing that it was separate from the clinic
assessment and their consent was taken for participa-
tion. Participation by Centres was voluntary.
The Centre staff gather information from applicants
relating to sight, hearing, locomotor system, cardio-
vascular, neurological and renal diseases, diabetes
mellitus, mental disorders, medication use, alcohol
and drug related problems.5,8 Additionally, Spanish
legislation (Royal Decree 772/1997) decrees that ‘per-
ceptual motor skills’ be evaluated, including: (i) speed
anticipation, (ii) senso-motor co-ordination, (iii) mul-
tiple-reaction time. A report is issued after this pro-
cess stating whether the person is: (i) fit, (ii) fit with
restrictions, (iii) suspended or (iv) unfit.5,8
The present study collected information relating to:
(i) socio-demographic aspects, (ii) medical pathology,
(iii) medication use, (iv) alcohol consumption patterns
and alcohol related problems (dependence)5 and (v)
the Centre’s evaluation of psycho-physical abilities.
Drivers were asked about medicaments they were
consuming when the interview was carried out, the
registered name of the medicine they were using,
the length of time they had been taking them and
the reason for taking them. Information was recorded
concerning up to four different medicinal drugs. Each
registered pharmaceutical preparation was coded fol-
lowing the Anatomical Therapeutic Chemical classifi-
cation system. Habitual use was defined as using the
drug on a daily basis for at least 1 month.7 The Sum-
mary of Product Characteristics (SPC) for each med-
ication was reviewed and it was recorded whether
there was any warning about the medication’s effect
on fitness to drive. The frequency of alcohol consump-
tion and the average quantity of pure alcohol con-
sumed in grams/day was analyzed, as well as the
presence of alcohol related problems (dependence,
DSM IV criteria5).
Statistical analysis was performed using variance
analysis and chi-square test with results expressed in
odds ratio (OR) and 95% confidence interval (CI),
when appropriate. SAS software version 6.07 was
used and p-values of <0.05 were considered signifi-
cant.
RESULTS
24.7% of drivers chronically consume medicaments
(Table 1), it being more frequent among men than
women (OR 1.08, 95% CI 0.97–1.20) and increasing
with age ( p< 0.0001). The mean (SD) number of
medicaments consumed among chronic consumers is
1.28 0.56 (1.26 0.55 women, 1.29 0.56 men;
F¼ 0.64, p> 0.05) increasing with age (F¼ 12.0,
p< 0.0001). The therapeutic groups most frequently
consumed are: cardiovascular system (7.8% of popu-
lation) followed by alimentary tract and metabolism
(4.8%) and central nervous system (4.3%) (Table 2).
6.8% of the population consume medicaments and
alcohol on a daily basis (Table 1) (27.4% of these take
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medication habitually). It is more frequent among
men, than women, (OR 4.73, 95% CI 3.31–5.75)
and increases with age ( p< 0.0001). The mean SD
grams/day of pure alcohol consumption among those
consuming both alcohol and medicaments is
27.52 18.29 grams/day (21.08 16.38 women,
28.28 18.50 men; F¼ 8.03, p< 0.05), and varies
with age, the maximum being among the 25–34 age
group, decreasing thereafter (F¼ 4.0, p< 0.01).
In the Centre’s examination, 88.3% were ‘fit’
(91.5% of those not taking medicaments, and 78.6%
of those habitually consuming medicaments, OR
2.92, 95% IC 2.54–3.35); 10.3% were ‘fit with restric-
tions’ (7.6% and 18.4% respectively, OR 0.36, 95% IC
0.31–0.42); 1.2% were ‘suspended’ (0.7% and 2.5%,
OR 0.27, 95% IC 0.18– 0.41); and 0.3% were ‘unfit’
(0.2% and 0.4%, OR 0.47, 95% IC 0.20–1.11).
For 20% of the medication used chronically (513
out of 2566), there was a warning in the SPCs about
the effect of the medication on the ability to drive
(Table 2). This data shows that 4.9% of drivers
(20% of the drugs taken chronically by 24.7% of the
population) were using medication that impairs driv-
ing performance. When the final results of the medical
examinations of those who were taking medicaments
chronically were compared with ‘whether there was a
warning about the effect on fitness to drive on the
package inserts of the medication’, or not it was found
that in the cases considered to be ‘unfit’, all nine of
them (100%) were taking medicaments that had a
warning. Of those considered to be ‘suspended’, 26
out of 51 (51%) were taking medicaments with a warn-
ing. Of those considered ‘fit with restrictions’, 140 of
the 368 (38%) were taking medicaments with a warn-
ing and of those considered ‘fit’, 338 of the 1572
(21.5%) were taking medicaments with a warning.
Those found ‘unfit’, who were also consuming
medicaments (9 cases), all suffered from some patho-
logical process included in the list of pathologies that
can interfere with fitness to drive (Royal Decree 772/
1997 and Council Directive 91/439 EEC). They were
also consuming medicine that could potentially inter-
fere with fitness to drive (there was a warning in the
SPCs). Case 1 was taking a tryciclic antidepressant
drug; case 2 was taking a tryciclic antidepressant drug
plus a long acting benzodiazepine; case 3 was taking a
long acting benzodiazepine; case 4 was taking a first
generation antihistamine H-1 drug; case 5 was taking
an antipsychotic drug; case 6 was taking an antiepilep-
tic drug; case 7 was taking an antihypertensive drug
plus a nonsteroidal antiinflammatory drug; case 8
was taking an antihypertensive drug plus a nonsteroi-
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and finally case 9, was taking an antihypertensive drug
plus a nonsteroidal antiinflammatory drug plus a
hypolipidemic drug and an antiarrhythmic drug. Six
of these nine patients had no alcohol related problem
(five were tea-totallers), and three had a diagnosed
dependence on alcohol. The percentage of ‘unfit’
cases increased with respect to the number of medica-
ments consumed (1¼ 0.3%, 2¼ 0.5%, 3¼ 1.2%,
4¼ 9.1%), likewise with respect to those found ‘fit
with restrictions’ (1¼ 16.2%, 2¼ 21.2%, 3¼ 43.2%,
4¼ 45.4%).
DISCUSSION
The present study shows that medicaments consump-
tion is frequent (24.7%) among drivers attending
Medical Driving Test Centres. In a study carried out
earlier in Spain in a representative sample of drivers,7
chronic medicament consumption was observed in
17.3%, a little lower than in the present study. Like-
wise, studies carried out previously in surrounding
countries show similar medicament consumption.9
Nevertheless, a comparison of such data is difficult
as there is little standardization, and different meth-
odologies are used with different reference popula-
tions.
In that earlier study, carried out on the driving
population,7 chronic medication use was found to be
more frequent among females (18%) than among
males (16.9%), as well as the average number of med-
ications used (2.16 vs 1.87, respectively). Data from
the Spanish general population based on the National
Health Survey,10 shows that 47.1% of the population
over 16 years had used some kind of medication in the
two previous weeks, more frequently among females
(53.2%) than males (40.5%). The average number of
medications was also higher in females (1.6) than in
males (1.4). However, in the present study there were
no significant differences between males and females
regarding frequency (23.8% females and 25.3%
males) and number of medications used (1.29 for
males and 1.26 for females) and the mean number
of medicines taken was lower than in previous studies,
both for the drivers population7 and the general popu-
lation.10
Apart from the fact of the limitations of data com-
parison between the different population sample
sources (drivers attending medico-psychological cen-
tres for evaluation of their fitness to drive, general
driving population and general population), there are
two aspects to take into account. The first is that, of
the 19 million driving licences in Spain, about 34%
correspond to women, and in three out of four cases,
the women are under 45 years of age. This implies
that, of those female drivers who go to renew their
licence, the majority are quite young and presumably
healthy. This could account in part for the observed
pattern of medication use by women. The second,
deals with the possible reticence to tell the truth for
fear of a negative report on their fitness to drive,
although drivers were clearly informed that the infor-
mation would be used only for scientific data and had
no administrative and/or legal consequences. Thus,
regarding patterns of alcohol consumption,5 the
Table 2. Types of medication used by Spanish drivers
Class of medication Total Male Female OR (95% CI) Warning in the SPC about the
n¼ 8043 n¼ 5435 n¼ 2608 Male/female effect of the medication on
(%) (%) (%) the ability to drive or use
machinery (%)
Alimentary tract and metabolism 4.8 5.2 4.1 1.26 (1.01–1.59) 5.6
Blood and blood forming organs 4.2 4.8 2.9 1.64 (1.27–2.13) 0.4
Cardiovascular system 7.8 9.3 4.8 2.03 (1.66–2.48) 25.7
Dermatologicals 0.8 0.7 0.8 0.91 (0.53–1.55) 0.0
Genito-urinary system and sex 2.1 1.3 3.9 0.32 (0.23–0.43) 0.7
hormones
Systemic hormonal preparations, 0.9 0.3 2.3 0.12 (0.07–0.22) 0.0
excluding sex hormones
General antiinfectives for systemic use 0.8 0.9 0.6 1.33 (0.76–2.32) 4.5
Antineoplastic and 0.0 0.1 0.0 0.99 (0.99–1.00) 0.0
inmunomodulating agents
Musculoskeletal system 2.7 3.0 1.8 1.68 (1.21–2.32) 5.4
Central nervous system 4.4 4.1 5.0 0.80 (0.64–1.00) 32.2
Respiratory system 3.0 2.8 3.4 0.81 (0.62–1.06) 24.8
Sensory organs 0.2 0.2 0.3 0.82 (0.32–2.09) 0.0
Various 0.2 0.1 0.2 0.55 (0.18–1.66) 0.0
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reported frequency of drinking does not differ from
other studies, while the amount of alcohol intake
was noticeably lower. Therefore, regarding medi-
cines, we can not exclude the fact that the low average
of medicines taken could reflect an underreporting of
all medicines taken.
As for joint alcohol/medicament consumption,
27.4% of drivers who were habitually taking medica-
tion also consumed alcohol on a daily basis. This con-
firms previous findings.7 This association may lead to
a greater risk of interactions, deterioration in the psy-
chomotor performance and an alteration of the fitness
to drive. Physicians and chemists should pay greater
attention to this aspect. In the present study of those
habitually consuming medicaments, a high percentage
(78.6%) are ‘fit to drive’ or ‘fit with restrictions’
(18.4%). Only 0.45% was considered ‘unfit’. All suf-
fered from a pathological process included in the list
of pathologies and were consuming a medicinal drug,
both of which could potentially interfere with the fit-
ness to drive. A third also suffered from alcohol
dependence. When we consider those taking medica-
ments with a warning about their effect on the capa-
city to drive, a high percentage were still considered
to be ‘fit to drive’ (65.8%) or ‘fit with restrictions’
(27.3%). Only 5.1% were considered to be ‘sus-
pended’ and 0.4% were considered ‘unfit’. There are
no studies within the EU analyzing these aspects.
Current European legislation (CD 91/439/EEC)
does not permit the issuing or renewal of driving
licences for those without adequate driving ability,
including several medical conditions and medication
use (‘which can hamper the ability to drive safely’).
The problem arises when evaluating fitness in clinical
practice. This legislation is difficult to apply as the
relation between illness, medication and fitness to
drive is highly complex.6,11 The side-effects of medi-
caments vary from person to person and are com-
pounded by polypharmacy and self-medication.
However, medicaments are used to treat illnesses
and it is sometimes the illness itself that impairs fit-
ness to drive. Moreover, the consequences for driving
and not taking the medication can be worse. Even so,
the medication prescribed may have an effect on the
psychomotor performance.
That is, data from the present study indicate that, in
clinical practice, the decision about whether a driver is
fit to drive or not is based on individual clinical eva-
luation of each patient where the binomial illness–
medication cannot be separated. In fact, a high per-
centage of those taking medicaments with a warning
about their effect on driving ability are considered
‘fit’, in spite of the fact that the law says otherwise.
The difficulties of implementing this directive have
already been pointed out and the suggestion ‘to adapt
driving licence requirements in order to permit al-
lowances or restrictions for drivers using chronic
treatments influencing driving’12 has been made.
However doctors who prescribe medicaments to dri-
vers should take note of the law and the legal reper-
cussions and make an effort to prescribe the
medicament that least affects the capacity to drive,
to avoid both the risk of being involved in a traffic
accident and that of losing their driving licence.
What can be done is to prescribe the safest medica-
ment, avoid polypharmacy and ensure that alcohol is
not consumed.13 It must be said that not all medica-
ments affect fitness to drive equally. Within the EU,
package inserts include a statement regarding the
medication’s effects on fitness to drive or use machin-
ery. A three-tier classification of medicaments on this
basis has been accepted: (i) presumed to be safe or
unlikely to produce an effect, (ii) likely to produce
minor or moderate adverse effects, (iii) likely to pro-
duce severe effects or presumed to be potentially dan-
gerous (CPMP, III/9. 163/90 de la CEE).6,14 This
classification (which has not yet been implemented
in the EU) would be extremely useful when selecting
medicaments for drivers, and for evaluating fitness to
drive when taking medication.6 Recently some coun-
tries like Belgium15 and Spain16 have introduced a
Drug Categorization System. France has introduced
such classification only for antihistamines H117 and
a pictogram has also recently been introduced in the
package of drugs affecting driving.
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